Economic impact of the introduction of an acellular pertussis vaccine in Canada: A 6-year analysis

Vaccine

Volumn 28, Issue 3, 2010, Pages 714-723

  Iskedjian, Michael ^a   De Serres, Gaston ^b   Einarson, Thomas R ^a   Walker, John H ^a,c  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c BROCK UNIVERSITY   (Canada)

Author keywords

Acellular vaccine; Canada; Economic evaluation; Pertussis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; PERTUSSIS VACCINE;

ARTICLE; CANADA; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MONITORING; DRUG SENSITIVITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNIZATION; MODEL; MONTE CARLO METHOD; MORBIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; MALE; PERTUSSIS VACCINE; TREATMENT OUTCOME; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 71149107865     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.079     Document Type: Article

References (59)

1. Health Canada. Whooping cough (pertussis). Health Canada; 2005. Available: http://www.hc-sc.gc.ca/iyh-vsv/diseases-maladies/cough-toux_e.html (accessed April 18, 2006).
2. Galanis E., King A., Varughese P., and Halperin S. Changing epidemiology and emerging risk groups for pertussis. CMAJ 174 4 (2006) 451-452
3. Halperin S., Bortolussi R., MacLean D., and Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia enhanced pertussis surveillance program. J Pediatr 115 5 Part 1 (1989) 686-693
4. Halperin S. Acellular pertussis vaccine has arrived in Canada, finally. Can Fam Physician 43 (1997) 1581-1582
5. Bettinger J., Halperin S., De Serres G., Scheifele D., and Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 26 1 (2007) 31-35
6. Decker M., Edwards K., Steinhoff M., Rennels M., Pichichero M., Englund J., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96 3 part 2 (1995) 557-566
7. Gustafsson L., Hallander H., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 6 (1996) 349-355
8. Halperin S., Wang E., Law B., Mills E., Morris R., Déry P., et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the immunization monitoring program-active (IMPACT). Clin Infect Dis 28 6 (1999) 1238-1243
9. Caro J., Getsios D., El-Hadi W., Payne K., and O'Brien J. Pertussis immunization of adolescents in the United States. An economic evaluation. Pediatr Infect Dis J 24 5 (2005) S75-S82
10. de Greeff S., Lugnér A., van den Heuvel D., Mooi F., and de Melker H. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 27 13 (2009) 1932-1937
11. Edmunds W., Brisson M., Melegaro A., and Gay N. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20 9-10 (2002) 1316-1330
12. Iskedjian M., Einarson T., O'Brien B., De Serres G., Gold R., Gemmill I., et al. Economic evaluation of a new acellular vaccine for pertussis in Canada. Pharmacoeconomics 19 5 part 2 (2001) 551-563
13. Iskedjian M., Walker J., and Hemels M. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22 31-32 (2004) 4215-4227
14. Iskedjian M., Walker J., De Serres G., and Einarson T. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Quebec, Canada. Paediatr Drugs 7 2 (2005) 123-136
15. Purdy K., Hay J., Botteman M., and Ward J. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 39 1 (2004) 20-28
16. Scuffham P., and McIntyre P. Pertussis vaccination strategies for neonates-an exploratory cost-effectiveness analysis. Vaccine 22 21-22 (2004) 2953-2964
17. Tormans G., van Doorslaer E., van Damme P., Clara R., and Schmidt H. Economic evaluation of pertussis prevention by whole-cell and acelullar vaccine in Germany. Eur J Pediatr 157 5 (1998) 395-401
18. Briggs A., Claxton K., and Sculpher M. Decision modelling for health economic evaluation (2006), Oxford University Press, Oxford, United Kingdom
19. Public Health Agency of Canada. Canada Communicable Disease Report. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on pertussis vaccine. vol. 23 (ACS-3); 1997. p. 1-15. Canada, Public Health Agency of Canada.
20. Public Health Agency of Canada. National Consensus Conference on Pertussis. CCDR. vol. 29s3; 2003. Canada, Public Health Agency of Canada. p. 1-16.
21. Statistics Canada (91-213-XPB). Annual Demographic Statistics, 2004. Ottawa, Statistics Canada; 2005. p. 7101.
22. StatsCan. Mortality - Summary list of causes, 1997. No. 84F0209XIB; 1999. Canada, Statistics Canada. p. 1-30.
23. StatsCan. Deaths, by age group and sex, Canada, provinces and territories, annual (2112 series). Table 102-0504-2112 Series; 2005. Canada, Statistics Canada. p. 1-3.
24. StatsCan. Mortality - summary list of causes, 1991. Catalogue No. 84-209. Ottawa, Canada, Ministry of Industry, Science and Technology; 1994. p. 16-19.
25. StatsCan. Mortality - summary list of causes, 1999. Catalogue No. 84F0209XPB. Canada, Statistics Canada; 2002. p. 1-192.
26. StatsCan. Mortality - summary list of causes, 1995. Catalogue No. 84-209-XPB. Ottawa, Canada, Minister of Industry; 1997. p. 18-21.
27. StatsCan. Mortality - summary list of causes, 1994. Catalogue No. 84-209-XPB. Ottawa, Canada: Minister of Industry; 1996. p. 18-21.
28. StatsCan. Mortality - summary list of causes, 1993. Catalogue no. 84-209-XPB. Ottawa, Canada: Minister of Industry; 1996. p. 18-21.
29. StatsCan. Mortality - summary list of causes, 1992. Catalogue No. 84-209 Annual. Ottawa, Canada: Minister of Industry, Science and Technology; 1995. p. 18-21.
30. StatsCan. Profile of the Canadian population by age and sex: Canada ages. Catalogue No. 96F0030XIE2001002. Canada, Statistics Canada; 2002. p. 3-28.
31. Bettinger J, Halperin S, De Serres G, Scheifele D, IMPACT Investigators. Epidemiology of Hospitalized Pertussis after Change from Whole-Cell to Acellular Pertussis Vaccine. Health Canada; 2004. Available: http://www.phac-aspc.gc.ca/cnic-ccni/2004/pres/_pdf-mon-lun/1_BETTINGER_JULIE_Monday_511cf.pdf (accessed March, 2006).
32. World Health Organization. Pertussis Surveillance. WHO/V&B/01.19. Geneva, Switzerland: World Health Organization; 2001. p. 1-60.
33. Center for Disease Control and Prevention. Pertussis. Epidemiology and prevention of vaccine-preventable diseases: the pink book. 9th ed. (January 2006). Waldorf, Maryland: Public Health Foundation, Publications; 2006.
34. Tozzi A., Celentano L., Ciofi degli Atti M., and Salmaso S. Diagnosis and management of pertussis. CMAJ 172 4 (2005) 509
35. Siegel J., and Swanson D. The methods and materials of demography. 2nd ed. (2004), Elsevier Academic Press, London
36. Public Health Agency of Canada. Incidence over time - pertussis, both sexes combined (Incl. Not Specified), Canada, 1989-2004: Rate per 100, 000. Public Health Agency of Canada; 2005. p. 1-2.
37. De Serres G., Shadmani R., Duval B., Boulianne N., Déry P., Fradet M., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 182 1 (2000) 174-179
38. Deeks S., De Serres G., and Boulianne N. Failure of physicians to consider the diagnosis in children with pertussis. Clin Infect Dis 28 4 (1999) 840-846
39. Tan T., Trindale E., and Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 24 5 (2005) S10-S18
40. Manga P., Scott J., and Chung P. A benefit cost analysis of changing to an acellular vaccine for pertussis in Canada (1997), Pran Manga and Associates, Ottawa
41. Bentsi-Enchill A., Halperin S., Scott J., MacIsaac K., and Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 15 3 (1997) 301-306
42. De Serres G., Boulianne N., Duval B., Déry P., Rodriguez A., Massé R., et al. Effectiveness of a whole cell pertussis vaccine in child-care centres and schools. Pediatr Infect Dis J 15 6 (1996) 519-524
43. Li J., and Taylor B. Childhood immunisation and family size. Health Trends 25 1 (1993) 16-19
44. McWha L., MacArthur A., Badiani T., Schouten H., King A., and Tam T. Measuring up: results from the National Immunization Coverage Survey, 2002. Can Commun Dis Rep 30 5 (2004) 37-50
45. Public Health Agency of Canada. Childhood pertussis immunization status as reported by parents and the completeness of public-health and physician records in Nova Scotia, vol. 22-24. Canada, Public Health Agency of Canada; 1996. p. 1-6.
46. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334 6 (1996) 341-348
47. Moore D., Le Saux N., Scheifele D., and Halperin S. Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J 23 6 (2004) 568-571
48. StatsCan. Consumer price index (CPI), 2001 basket content, monthly (index, 1992 = 100) [Health Care]. Table 326- 0001 1,2,3,4,5,20 -- Consumer Price Index - 2301 CANSIM Table; 2006. p. 1-12. Canada, Statistics Canada. Available: http://cansim2.statcan.ca (accessed October 6, 2006).
49. Health Canada. National Consensus Conference on Pertussis. Conference May 25-28, 2002, vol. 2953. Ottawa, Canada; 2003. p. 1-33.
50. Gold R, Déry P, Halperin S, Law B, MacDonald N, Scheifele D et al. Pertussis in children hospitalized at five Canadian pediatric tertiary care centres. Can Commun Dis Rep 1994;20(4):31-4.
51. Ministry of Health and Long-term Care. Schedule of Benefits for Physician Services under the Health Insurance Act. Toronto, Ontario, Ontario Ministry of Health and Long-Term Care; 2005.
52. Ministry of Health and Long-term Care. Ontario Drug Benefit Formulary/Comparative Drug Index No. 39, effective September 27, 2005. 19M/05/96, Part I-PartXII. Toronto, Ontario, Ontario Ministry of Health and Long-Term Care; 2005.
53. Center for Disease Control and Prevention. CDC Growth Charts: United States. United States, National Center for Health Statistics; 2000. p. 1-7. Available: http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/charts.htm (accessed February, 2006).
54. BenefitsWorld. Provincial trends - dispensing fees and ingredient costs - Update. July 31, 2000. Revised: January 12, 2005. Available: http://www.benefitsworld.com/AA/Drug/Presc/Cdn_DIN_Costs_Update98-00.asp (Accessed March 29, 2006).
55. Maritime Life. ESI Canada, 2003 Drug Trend Report; 2003. p. 1-11. Available: http://groupbenefits.manulife.com/canada/GB_V2.nsf/LookupFiles/MaritimeBulletinMaritimeBulletin1404/CAD $File/BenefitsBulletin14English.pdf (accessed March 29, 2006).
56. Ontario Case Costing Project. Average Pediatric Nursing Costs for Bordetella Pertussis. Ontario Case Costing Project. September 12 1997. 20 Adelaide Street East, Toronto, ON, M5G 2T6 2002.
57. StatsCan. Average hourly wages of employees by selected characteristics and profession, unadjusted data, by province (monthly); 2005. Available: http://www40.statcan.ca/l01/cst01/labr69a.htm?sdi=average%20hourly%20wages%20employees%20selected (accessed April, 2006).
58. De Serres G. Morbidity of pertussis in adolescents and adults. Quebec Ministry of Health; 1999.
59. CADTH. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. 2006. Ottawa, ON, Canada: Canadian Agency for Drugs and Technologies in Health; 2006. p. 1-46.